Maynooth Graduate Zoë O’Sullivan Shortlisted for James Dyson Award

URGENT UPDATE: Maynooth graduate Zoë O’Sullivan has just been shortlisted for the prestigious 2025 James Dyson Award for her innovative device, Lymphia. This recognition places her among the top 20 entries worldwide, highlighting a groundbreaking solution for chronic health care challenges.

Lymphia addresses a significant gap in accessible lymphatic drainage therapy, targeting conditions such as lymphoedema and lipedema, which affect millions globally. Despite their prevalence, these conditions remain under-recognized, causing persistent swelling and emotional distress for those affected.

O’Sullivan’s device empowers patients to perform Manual Lymphatic Drainage (MLD) at home, reducing reliance on costly treatments and improving quality of life. Current treatments often involve expensive physiotherapy sessions or compression devices, which can be unaffordable and time-consuming. Lymphia’s design uses 10mm steel balls that enhance comfort and effectiveness by precisely stimulating lymphatic vessels.

“I am so thrilled to have been selected as part of the Top 20 for this year’s James Dyson Award,” O’Sullivan expressed. “Words really cannot do it justice. I’m incredibly grateful and delighted by the recognition of my work, and the awareness this can bring for lymphoedema and its treatment.”

The device also features an integrated pressure feedback system with a traffic light color indicator, guiding users to apply the optimal level of force. An accompanying mobile application provides step-by-step instructions in professional MLD techniques, combating misinformation and helping users achieve effective results.

The global winners, selected by Sir James Dyson, will be announced on 5 November 2025. The winning inventions will receive a grant of €36,000 to support further development and commercialization, making this an essential moment for innovators like O’Sullivan.

This announcement comes at a critical time when awareness about lymphatic conditions is growing. With up to 30% of breast cancer survivors affected by lymphoedema and around 12% of women globally suffering from lipedema, O’Sullivan’s work is set to make a significant impact.

As the announcement date approaches, all eyes will be on the innovations emerging from the James Dyson Award. O’Sullivan’s Lymphia stands out as a beacon of hope for those struggling with chronic lymphatic conditions, ensuring that patients can take control of their health with confidence.

Stay tuned for updates as this story develops, and celebrate the innovations that have the potential to change lives!